Jonathan J. Lyons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonathan J. Lyons has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
David González-De-Olano
Allergology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
1 shared publication- Hannah Shin
Division of Allergy & Immunology, Department of Medicine, University of California San Diego, La Jolla, USA
1 shared publication Peter Korošec
University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia; Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
1 shared publication
Latest Publications
- 25 October 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (12) , 3180-3186
Alpha-Tryptase Overexpression as a Modifier of Mast Cell–Mediated Reactions
- 25 October 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (12) , 3180-3186
Alpha-Tryptase Overexpression as a Modifier of Mast Cell–Mediated Reactions
- 1 January 2025
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 46 (1) , 4-10
Appraisal of the evidence linking hereditary α-tryptasemia with mast cell disorders, hypermobility and dysautonomia
Since its first description more than a decade ago, our understanding of the clinical impact of hereditary alpha-tryptasemia has continued to evolve. First considered to be a genetic disorder with a subset of patients having a syndromic presentation composed of connective tissue abnormalities, symptoms of autonomic dysfunction, and findings of mast cell activation, we now know that hereditary alpha-tryptasemia is a common genetic trait and modifier of mast cell‐mediated reactions. More recent studies have shown some previously held associations with congenital hypermobility and postural orthostatic tachycardia syndrome (POTS) to be lacking, and illuminated previously unappreciated associations with clonal and nonclonal mast cell disorders. With the discovery of heterotetrameric tryptases and demonstration of their unique functional activities, the importance of tryptase gene composition in general has begun to take focus. Hereditary alpha-tryptasemia exists at the end of a spectrum of alpha-tryptase expression and as a natural overexpression model of this protein, brought to the fore the potential of tryptase genotyping as a genetic biomarker for anaphylaxis severity. These data and future studies hold the promise of enhancing our understanding of the role that tryptases play in health and disease.
- 1 January 2025
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 46 (1) , 4-10
Appraisal of the evidence linking hereditary α-tryptasemia with mast cell disorders, hypermobility and dysautonomia
Since its first description more than a decade ago, our understanding of the clinical impact of hereditary alpha-tryptasemia has continued to evolve. First considered to be a genetic disorder with a subset of patients having a syndromic presentation composed of connective tissue abnormalities, symptoms of autonomic dysfunction, and findings of mast cell activation, we now know that hereditary alpha-tryptasemia is a common genetic trait and modifier of mast cell‐mediated reactions. More recent studies have shown some previously held associations with congenital hypermobility and postural orthostatic tachycardia syndrome (POTS) to be lacking, and illuminated previously unappreciated associations with clonal and nonclonal mast cell disorders. With the discovery of heterotetrameric tryptases and demonstration of their unique functional activities, the importance of tryptase gene composition in general has begun to take focus. Hereditary alpha-tryptasemia exists at the end of a spectrum of alpha-tryptase expression and as a natural overexpression model of this protein, brought to the fore the potential of tryptase genotyping as a genetic biomarker for anaphylaxis severity. These data and future studies hold the promise of enhancing our understanding of the role that tryptases play in health and disease.
- 9 March 2024
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 24 (4) , 199-209
Alpha-Tryptase as a Risk-Modifying Factor for Mast Cell–Mediated Reactions
Purpose of Review To provide an overview on the current understanding of genetic variability in human tryptases and summarize the literature demonstrating the differential impact of mature tryptases on mast cell–mediated reactions and associated clinical phenotypes. Recent Findings It is becoming increasingly recognized that tryptase gene composition, and in particular the common genetic trait hereditary alpha-tryptasemia (HαT), impacts clinical allergy. HαT has consistently been associated with clonal mast cell disorders (MCD) and has also been associated with more frequent anaphylaxis among these patients, and patients in whom no allergic trigger can be found, specifically idiopathic anaphylaxis. Additionally, more severe anaphylaxis among Hymenoptera venom allergy patients has been linked to HαT in both retrospective and prospective studies. An increased relative number of α-tryptase-encoding gene copies, even in the absence of HαT, has also been associated with systemic mastocytosis and has been shown to positively correlate with the severity of mast cell–mediated reactions to vibration and food. These findings may be due to increased generation of α/β-tryptase heterotetramers and differences in their enzymatic activity relative to β-tryptase homotetramers. Summary HαT is a naturally occurring overexpression model of α-tryptase in humans. Increased relative α-tryptase expression modifies immediate hypersensitivity symptoms and is associated with more frequent and severe mast cell–mediated reactions, ostensibly due to increased α/β-tryptase heterotetramer production.
- 9 March 2024
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 24 (4) , 199-209
Alpha-Tryptase as a Risk-Modifying Factor for Mast Cell–Mediated Reactions
Purpose of Review To provide an overview on the current understanding of genetic variability in human tryptases and summarize the literature demonstrating the differential impact of mature tryptases on mast cell–mediated reactions and associated clinical phenotypes. Recent Findings It is becoming increasingly recognized that tryptase gene composition, and in particular the common genetic trait hereditary alpha-tryptasemia (HαT), impacts clinical allergy. HαT has consistently been associated with clonal mast cell disorders (MCD) and has also been associated with more frequent anaphylaxis among these patients, and patients in whom no allergic trigger can be found, specifically idiopathic anaphylaxis. Additionally, more severe anaphylaxis among Hymenoptera venom allergy patients has been linked to HαT in both retrospective and prospective studies. An increased relative number of α-tryptase-encoding gene copies, even in the absence of HαT, has also been associated with systemic mastocytosis and has been shown to positively correlate with the severity of mast cell–mediated reactions to vibration and food. These findings may be due to increased generation of α/β-tryptase heterotetramers and differences in their enzymatic activity relative to β-tryptase homotetramers. Summary HαT is a naturally occurring overexpression model of α-tryptase in humans. Increased relative α-tryptase expression modifies immediate hypersensitivity symptoms and is associated with more frequent and severe mast cell–mediated reactions, ostensibly due to increased α/β-tryptase heterotetramer production.